Advanced in Autism Spectrum Disorder

Dr. Robert L. Findling

Child and Adolescent Psychiatry | Psychiatry
Mcv Associated Physicians
1308 Sherwood Ave, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Advanced in Autism Spectrum Disorder
Mcv Associated Physicians
1308 Sherwood Ave, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Findling is a Child and Adolescent Psychiatrist and a Psychiatrist in Richmond, Virginia. Dr. Findling is rated as an Advanced provider by MediFind in the treatment of Autism Spectrum Disorder. His top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), Autism Spectrum Disorder, and Schizophrenia. Dr. Findling is currently accepting new patients.

His clinical research consists of co-authoring 290 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles and participated in 1 clinical trial in the study of Autism Spectrum Disorder.

Specialties
Child and Adolescent Psychiatry
Psychiatry
Licenses
Child & Adolescent Psychiatry in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1308 Sherwood Ave, Richmond, VA 23220

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Enrollment Status: Terminated
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drug: NaBen®
Study Phase: Phase 2/Phase 3
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
Enrollment Status: Terminated
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drug: Carbamazepine
Study Phase: Phase 4
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
Enrollment Status: Completed
Publish Date: December 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

290 Total Publications

Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial.
Journal: CNS drugs
Published: July 10, 2025
Similar Doctors
Distinguished in Autism Spectrum Disorder
Dr. Adam T. Kaul
Psychiatry
Distinguished in Autism Spectrum Disorder
Dr. Adam T. Kaul
Psychiatry

Otl Community Services

9201 Arboretum Pkwy, Suite 300, 
North Chesterfield, VA 
 (8.3 miles away)
855-355-7001
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Kaul is a Psychiatrist in North Chesterfield, Virginia. Dr. Kaul is rated as a Distinguished provider by MediFind in the treatment of Autism Spectrum Disorder. His top areas of expertise are Autism Spectrum Disorder, Bipolar Disorder (BPD), Post-Traumatic Stress Disorder (PTSD), and Generalized Anxiety Disorder (GAD). Dr. Kaul is currently accepting new patients.

Advanced in Autism Spectrum Disorder
Dr. Charles E. Hall
Child and Adolescent Psychiatry | Psychiatry
Advanced in Autism Spectrum Disorder
Dr. Charles E. Hall
Child and Adolescent Psychiatry | Psychiatry

Tucker Psychiatric Clinic Inc.

1000 Boulders Pkwy, Suite 202, 
North Chesterfield, VA 
 (5.9 miles away)
804-320-7881
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Hall is a Child and Adolescent Psychiatrist and a Psychiatrist in North Chesterfield, Virginia. Dr. Hall is rated as an Advanced provider by MediFind in the treatment of Autism Spectrum Disorder. His top areas of expertise are Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Autism Spectrum Disorder, and Major Depression. Dr. Hall is currently accepting new patients.

Advanced in Autism Spectrum Disorder
Dr. David W. Gould
Child and Adolescent Psychiatry | Psychiatry
Advanced in Autism Spectrum Disorder
Dr. David W. Gould
Child and Adolescent Psychiatry | Psychiatry

Tucker Psychiatric Clinic Inc.

1000 Boulders Pkwy, Suite 202, 
North Chesterfield, VA 
 (5.9 miles away)
804-320-7881
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Gould is a Child and Adolescent Psychiatrist and a Psychiatrist in North Chesterfield, Virginia. Dr. Gould is rated as an Advanced provider by MediFind in the treatment of Autism Spectrum Disorder. His top areas of expertise are Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Major Depression, and Autism Spectrum Disorder. Dr. Gould is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Findling's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile